High dose oral amiodarone loading exerts important hemodynamic actions in patients with congestive heart failure  by Gottlieb, Stephen S. et al.
560
High Dose Oral Amiodarone Loading Exerts Important Hemodynamic
Actions in Patients With Congestive Heart Failure
STEPHEN S. GOTTLIEB, MD, FACC, DAVID W. RIGGIO, MD, SALVATORE LAURIA, MD,
ROBERT W. PETERS, MD, STEPHEN R . SHOROFSKY, MD, PHD, MICHELLE LINES, RN,
DEBORAH FROMAN, RN, MICHAEL R. GOLD, MD, PHD, FACC
Baltimore, Maryland
Objectives . The purpose of this study was to use invasive
monitoring to analyze the hemodynamic effects of both a large
and a 48.b loading regimen of antirone in patients
with severe heart failure .
Background. Amiodarone is frequently used as an antiarrhyth-
mic agent in patients with congestive heart failure, but the Impact
of this agent on cardiac function remains controversial. Recent
successful experience with a rapid oral load of amiodarone makes
invasive testing of the hemodynamic effects of oral amiodarone in
such patients now feasible .
Methods . After baseline hemodynamic assessment (using
balloon-tipped pulmonary artery catheters) and electrocardio-
graphic measurements, 16 patients received 12 .5 mg/kg body
weight of amiodarone orally. Hemodynamic measurements were
obtained hourly for 4 h . Patients then received this dose an
additional seven times over the next 2 days . Hemodynamic
variables and QRS, QT and PR intervals were measured after
48 It of treatment .
The safety and efficacy of the long-term use of amiodarone in
patients with congestive heart failure are controversial .
Although amiodarone decreases the frequency of complex
ventricular arrhythmias in these very high risk patients ( 1 .2) .
it has not been proved to have a beneficial effect on mortal-
ity . Furthermore, the use of the drug entails risk (3). Amio-
darone is well known to cause pulmonary toxicity ; in addi-
tion, its hemodynamic safety has been questioned in clinical
studies. Some investigations (4) have reported the develop-
ment of symptoms of congestive heart failure in patients who
have received amiodarone for long periods . Other studies (2)
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Results. Vasodilation was seen between I and 3 it after drug
administration. Systemic vascular resistance decreased 326 :t 135
dynes-s-cm -5 , cardiac index increased 0.24 ± 0.08 liters/min per
m2 and mean arterial pressure decreased 6 ± 3 mm Hg (mean ±
SEM, all p < 0.05). After 48 h of amiodarone administration,
heart rate decreased 23 ± 3 beats/min (p < 0.005), stroke volume
increased 9 ± 3 ml (p < 0.095), cardiac index decreased 0 .23 ±
0.09 ml/min per m2 (p < 0.05), pulmonary capillary wedge
pressure increased 4 ± 1 mm Hg (p < 0.01), right atrial pressure
increased 3 :l : 1 mm Hg (p < 0.005) and QT and PR intervals were
markedly prolonged (p < 0.01).
Conclusions. Although the first dose caused vasodilation, a
complete loading regimen of amiodarone produced a decreased
heart rate with elevated filling pressures and decreased cardiac
index.
(J Am Coll Cardiol 1994,23 .-S60-4)
have found no adverse hemodynamic consequences of amio-
darone administration .
Hemodynamic studies of intravenous amiodarone have
consistently demonstrated both decreased myocardial con-
tractility and vasodilation, particularly in patients with left
ventricular dysfunction (5) . However, the solvent used in the
intravenous formulation (Tween 80) has important hemody-
namic effects, confounding extrapolation of these findings to
the use of oral amiodarone (6) . Indeed, one study (7) not
using Tween 80 as the solvent did not find vasodilation .
Further complicating the analysis of the hemodynamic ef-
fects of oral amiodarone has been the unusual pharmacoki-
netics of the drug. The prolonged tissue half-life of amio-
darone and long duration of loading regimens have
prevented accurate assessment of the drug's hemodynamic
effect .
Assessment of these effects of amiodarone in patients
with heart failure has also been limited in other ways . Many
studies (1) have assessed changes iii ejection fraction, but
these changes do not reliably indicate the clinical response to
a medication (8) . Other studies (9) have evaluated patients
with relatively normal left ventricular function and are not
applicable to patients with heart failure, who may exhibit
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adverse hemodynamic effects when given a medication that
causes no such problems in normal persons (10) .
Because most studies of the hemodynamic effects of
amiodarone have not been controlled and have used inseri-
sitive noninvasive assessments of cardiac function Me im-
pact of the use of this agent on cardiac function in patients
with heart failure remains conjectural . Recent successful
experience with a rapid oral load of amiodarone (11) makes
invasive testing of the hemodynamic effects of oral amio-
darone in such patients feasible . It is now possible to
determine the effects of a large single dose of the drug, and
a loading dose can be administered and evaluated within
48 h. Therefore, the purpose of this study was to use
invasive hemodynamic monitoring to analyze the hemody-
namic effects of amiodarone in patients with severe conges-
tive heart failure .
Methods
Study patients. We studied 16 patients with severe left
ventricular dysfunction who received amiodarone for the
treatment of ventricular arrhythmias. There were 15 men
and I woman, aged 42 to 73 years (mean age ± SEM 65 ± 2) .
All patients had a left ventricular ejection fraction <40% by
radionuclide angiography (range 11% to 33%, mean 21 ± 2) .
The cause of heart failure was ischemic heart disease in 11
patients and dilated cardiomyopathy in 5 . Fifteen patients
were in New York Heart Association functional class III and
one patient was in class IV . All patients were receiving
constant doses of digitalis, diuretic drugs and vasodilators .
Antiarrhythmic agents had not been administered for at least
five half-lives . This study protocol was approved by the
Human Volunteers Committee of the University of Mary-
land School of Medicine .
Hemodynamic measurements . After written informed
consent was obtained, right heart catheterization was per-
formed, and patients were permitted to rest overnight to
allow for the dissipation of hemodynamic changes related to
intravascular instrumentation . On the next morning, after all
cardioactive medications and food were withheld for 2:8 h,
the following hemodynamic variables were measured repeat-
edly in the fasting state until hemodynamic stability was
achieved : mean arterial pressure, heart rate, left ventricular
filling pressure, mean right atrial pressure and cardiac out-
put. All measurements were obtained with procedures that
have been described previously (12) . Cardiac output was
measured by the thermodilution technique, with three or
more 10-ml injections of 0° to 3°C 5% dextrose in water . To
ensure reproducible hemodynamic recordings, measure-
ments were not recorded as baseline vaiues until two com-
plete sets of measurements obtained L- 10 min apart demon-
strated <15% variation with respect to both cardiac output
and left ventricular filling pressure . Before each measure-
ment, the transducer was leveled to the same point of the
patient's midchest .
Each patient then received over 2 days, 100 mg/kg body
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Table 1. Effects of a 48-h Amiodarone Loading Regimen
values expressed are mean value ± SEM .
weight of oral amiodarone, divided into eight equally spaced
doses. All hemodynamic variables were reassessed hourly
for 4 h after administration of the first dose of the drug. The
patient's morning medications were then given (after com-
pletion of acute hemodynamic assessment), and the patient
was placed on his or her routine regimen. Forty-eight hours
after the initial amiodarone dose and after the patient had
received all the doses of amiodarone, hemodynamic mea-
surements were obtained in the same manner as the initial
baseline measurements . All food and cardioactive medicines
were again withheld for 8 h before assessment .
One patient did not have hemodynamic measurements
obtained on day I after baseline measurements because he
inadvertently received his usual cardiac medications after
the baseline assessment . This patient is included in the
comparison between baseline and 48-h measurements .
Electrocardiographic assessment . Before placement of
the Swan-Ganz catheter, QRS, QT and PR intervals were
determined in all patients . These assessments were repeated
immediately after the 48-h hemodynamic evaluation .
Statistical analysis. Comparisons of the baseline and 48-h
measurements were made by using the two-tailed Student t
test for paired data, with p < 0 .05 considered significant. The
values obtained at baseline and for 4 h after amiodarone
administration were compared with analysis of variance
(ANOVA) and the Fisher PLSD (Protected Least Significant
Difference) test
. Mean values ± SEM are given where
appropriate .
Results
Patient characteristics . All 16 patients had evidence
of
severe congestive heart failure (Table 1)
. The mean cardiac
index was 1 .83 ± 0 .11 liters/min per m
2
and mean pulmonary
capillary wedge pressure was 19 ± 2 mm Hg
. Baseline heart
rate ranged from 58 to 115 beats/min (mean 84 ± 4)
.
Tolerability . Despite the extremely high doses of amio-
Baseline
48 Is
p
value
Heart rate (bc-ts/mm) 84 ± 4 62 ± 3 < 0.005
Mean arterial i ressure 90 ± 3
89 ± 3
(mm Hg)
Pulmonary capillary wedge 19 ± 2 23 ± 2 < 0 .01
pressure (mm Hg)
Right atrial pressure 9 ± 2 12 ± 2
< 0 .005
(mm Hg)
Cardiac index (liters/min 1 .83 ± 0 .11 1 .60 ± 0 .09 < 0 .05
per m2 )
Systemic vascular resistance 2,033 ± 205 2 .186 ± 191
(dynes-s-cm -5 )
Stroke volume (ml) 42 ± 3 51 ± 4 < 0 .005
QRS comply (ms)
160 ± 20 163 ± 19
QTinterval (ms) 395 ± 11 491 ± 25 < 0 .005
PR interval (ms)
216
± 12 260
± 19 < 0 .01
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darone prescribed, most patients were able to receive all
eight doses. The patients received a mean of 6 .9 ± 0.4 g of
amiodarone (range 3.5 to 9.9). Four patients did not receive
the full prescribed dose . In one patient, three doses were
withheld because of marked bradycardia ; the heart rate had
decreased to 40 beats/min after five doses of amiodarone .
One dose of amiodarone was withheld in two patients
because of gastrointestinal symptoms . Because of a nursing
error, one other patient also received a total of seven doses
.Hemodynamic effects . Vasodilation was clearly seen after
a single dose of 12 .5 mg/kg of amiodarone (Fig . I) . The peak
effect was observed I to 3 h after drug administration . Mean
systemic vascular resistance decreased 326 ± 135
dynes-s-cm --' 2 h after drug administration, cardiac index
increased 0.24 ± 0 .08 liters/min per
in
2
after I h and mean
arterial pressure decreased 6 ± 3 mm Hg after 3 h (all p <
0.05). There were no early changes in heart rate, right atrial
pressure or pulmonary capillary wedge pressure .
The effects after 48 h of amiodarone administration were
very different from the early effects (Table 1) . The heart rate
decreased 23 ± 3 beats/min (p < 0 .005), and even though the
stroke volume increased 9 ± 3 ml (p < 0.005). the cardiac
index decreased 0 .23 ± 0.09 ml/min per m2 (p < 0.05) .
Pulmonary capillary wedge pressure increased 4 1 mm Hg
(p < 0.01) and right atrial pressure increased 3 1 mm Hg
(p < 0.005). The mean arterial pressure and systemic vascu-
lar resistance were no longer changed as compared with
baseline .
Electrophysiologic effects . At 48 h, significant electro-
physiologic effects were noted (Table 1) . As expected, the
QT and PR intervals were markedly prolonged (p < 0 .01)
and the heart rate decreased . The QRS interval was un-
changed .
3
2 3
Time (hours)
4
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Figure 1
. The hemodynamic effects for 4 h after a
single 12 .5-mg/kg amiodarone dose in patients with
severe congestive heart failure. A vasodilator effect
was seen between I and 3 h after drug administra-
tion . *Statistical significance (p < 0 .05) as compared
with the baseline (time 0) measurement . I = liters .
Discussion
This is the first study to evaluate the hemodynamic effects
of oral amiodarone invasively in patients with severe con-
gestive heart failure . It is necessary to evaluate the hemo-
dynamic effects of antiarrhythmic agents in patients with
congestive heart failure because studies performed in less
severely ill patients may not indicate potential adverse
hemodynamic effects . For example . encainide, tocainide and
mexiletine have minimal hemodynamic consequences in
persons with normal cardiac function, but produce a marked
increase in left ventricular filling pressure and decrease in
cardiac output when these agents are given to patients with
severe heart failure (13) . In the present study, the first dose
of amiodarone caused a vasodilator response with no clini-
cally apparent direct cardiac effect . With a 48-h loading
regimen, however, decreased cardiac index and elevated
pulmonary capillary wedge and right atrial pressures were
noted, despite an increased stroke volume . At this time,
clear electrophysiologic actions were present, as evidenced
by PR and QT prolongation and heart rate slowing .
Tolerability . A few previous studies (9,11) have sug-
gested that a loading regimen of 3 to 5 g of amiodarone can
be given every day without intolerable side effects . This
study extends these findings to patients with severe conges-
tive heart failure . Our patients with a mean baseline cardiac
index of 1 .8 liters/min per m 2 and a mean pulmonary
capillary wedge pressure of 19 mm Hg successfully received
a loading regimen over 2 days of 100 mg/kg of oral amio-
darone . As opposed to a previous study (9), amiodarone and
desethyl amiodarone serum concentrations were not used
(or needed) to administer these doses
Only two patients had a dose withheld because of gastro-
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intestinal side effects . One patient developed an electrophys-
iologic side effect of a markedly decreased heart rate, which
presumably would have taken longer to recognize with a
more prolonged loading regimen .
Early effects . Despite the potential influence in previous
studies (6) of the hemodynamic effects of the solvent Tween
80, we found that the early effects of a single oral dose of
amiodarone were similar to those seen after an intravenous
dose . Marked vasodilator
effects
are seen after intravenous
amiodarone administration (5,14,15) . Some studies (5,15)
using load-dependent indexes of contractility have also
suggested decreased contractility, but the present study did
not detect any clinically important immediate negative iso-
tropic effect . Of course, our study did not assess contractil-
ity, and the marked vasodilation could mask direct myocar-
dial effects .
Our findings are different from those of previous studies
of a single dose of oral amiodarone . For example, Mostow et
al . (9), who used invasive monitoring to study a wide range
of patients, did not notice the same vasodilator effect over
the 1st 24 h of high doses of amiodarone . However, the
patients in their study had less severe heart failure than that
ofthe patients we studied . Moderate congestive heart failure
was present in two-thirds of their patients, and the mean
pulmonary capillary wedge pressure was 14 mm Hg and
mean cardiac output was >4 liters/min. Furthermore, some
technical problems might have affected their results . The
Swan-Ganz catheter was placed immediately before baseline
measurements were obtained, and food and other medica-
tions were given concurrently .
Another study (16) of a single dose of 30 mg/kg of
amiodarone given to preoperative patients demonstrated a
20% decrease in cardiac index and an increased pulmonary
capillary wedge pressure. However, the dose was given as
long as 4 days before the follow-up hemodynamic evalua-
tion . In addition, the baseline hemodynamic evaluation was
made up to 2 weeks before operation and may not have
reflected the t,ue hemodynamic status of the patients imme-
diately before amiodarone administration .
Long-term effects. The present study shows that the most
important hemodynamic effect of a loading dose of amio-
darone (which causes clear electrophysiologic actions) is a
marked decrease in heart rate . Although this may have no
important hemodynamic effect in patients with normal car-
diac function, the consequent decreased cardiac index and
increased pulmonary capillary wedge pressure may exert
important hemodynamic actions in patients with heart fail-
ure .
It has been suggested (1) that long-term use of amio-
darone may actually improve cardiovascular hemodynam-
ics. However, this has not been confirmed. For example, no
differences in exercise time were noted between patients
receiving amiodarone and placebo (2) . Previous studies
(1,17) have often demonstrated maintenance of cardiac
function with amiodarone by demonstrating no change in
ejection fraction with the drug. However, conclusions from
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such studies are suspect. The ejection fraction is very
dependent on loading conditions and often does not detect
clinically significant changes in left ventricular function
. The
ejection fraction may fail to increase in patients who : ,nprove
clinically (8) and may remain unaltered in patients who
deteriorate symptomatically (18) . Invasive studies, such as
the present one, that directly measure the hemodynamic
consequences of an intervention are more relevant to the
clinical status of a patient than is analysis of ejection
fraction .
The long-term findings of the present study are consistent
with previous evaluations . In animals, long-term intravenous
amiodarone administration causes decreased heart rate, va-
sodilation and decreased contractility (19) . The heart rate at
rest decreases in patients with heart failure receiving amio-
darone, but this decrease did not cause a consequent de-
crease in cardiac index in a study by Cleland et al . (2) . That
their patients had less severe heart failure than those whom
we studied might explain the divergent results . Similarly,
exacerbation of heart failure by the administration of amio-
darone has been rarely reported in relatively healthy pa-
tients. Only 4% of 173 patients retrospectively analyzed had
heart failure reported as a possible side effect (20) .
Limitations. Ideally, the cardiodepressant risk of any
drug should be assessed after long-term therapy . However,
invasive determination of the hemodynamic effects of an
antiarrhythmic agent is not feasible because of the sponta-
neous variation that occurs over an extended period of
follow-up. We attempted to approximate the hemodynamic
effects seen during long-term therapy by evaluating the
response to a rapid loading regimen of amiodarone. How-
ever, we cannot exclude the possibility that the effects and
responses to long-term amiodarone administration might be
different .
This study was not placebo controlled, and it could be
argued that the changes we observed were secondary to
other factors . However, our study w .4s designed to prevent
such a bias . Before the administration --.f the drug, we
ensured stability of the baseline hemodynamic values, with
<10% variation (and no trend) among three determinations
over >_30 min . That we did not merely detect natural
hemodynamic fluctuations is supported by the vastly differ-
ent results of similar investigations of other agents that have
been performed in our laboratory (13) . Furthermore, our
findings are consistent with the known electrophysiologic
effects of amiodarone .
Conclusions. A rapid loading regimen permitted invasive
determination of the effects of an oral loading dose of
amiodarone in patients with severe congestive heart failure .
Although the first dose caused vasodilation, a complete
loading regimen produced a decreased heart rate with ele-
vated filling pressures and decreased cardiac index . This
response should be taken into account when considering
patients for amiodarone therapy .
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